Therapeutic apheresis: A review of complications and recommendations for Prevention and management

Journal of Clinical Apheresis

Volumn 26, Issue 5, 2011, Pages 243-248

  Mokrzycki, Michele H ^a   Balogun, Rasheed A ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

complications; TAA 2010; therapeutic apheresis

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; CALCIUM CARBONATE; CALCIUM ION; CITRATE SODIUM; CITRIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; EPHEDRINE; FIBRINOGEN; FRESH FROZEN PLASMA; GLUCONATE CALCIUM; HEPARIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; KININ; MAGNESIUM ION; POTASSIUM; PREDNISONE; RECOMBINANT HEPATITIS B VACCINE; SODIUM CHLORIDE;

ADULT; ALLERGIC REACTION; ANAPHYLAXIS; ANTICOAGULANT THERAPY; BLEEDING; BLOOD TRANSFUSION; BRAIN ISCHEMIA; CASE REPORT; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CORONARY ARTERY SPASM; DISTAL PARESTHESIA; FEMALE; FEVER; FOLLOW UP; GESTATIONAL AGE; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEPARIN INDUCED THROMBOCYTOPENIA; HEPATITIS; HUMAN; HYPOCALCEMIA; HYPOTENSION; HYPOVOLEMIA; IMMUNOADSORPTION; INTERNAL JUGULAR VEIN; LUNG EDEMA; LUNG EMBOLISM; METABOLIC ALKALOSIS; MUSCLE CRAMP; ORAL PARESTHESIA; PATIENT SAFETY; PLASMAPHERESIS; PREGNANT WOMAN; PREMEDICATION; PRURITUS; QT PROLONGATION; REMISSION; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; REVIEW; RIGOR; SEIZURE; SHOCK; STAPHYLOCOCCUS INFECTION; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; URTICARIA; VASCULAR ACCESS; VEIN THROMBOSIS; WHEEZING;

ADULT; ANTICOAGULANTS; BLOOD COMPONENT REMOVAL; DISEASE MANAGEMENT; FEMALE; HUMANS; INCIDENCE; PHARMACEUTICAL PREPARATIONS; PREGNANCY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RISK; THERAPEUTICS;

EID: 80054055419     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20303     Document Type: Review

References (32)

1. Mokrzycki MH, Rickles F, Kaplan AA, Kohn OF,. Thrombotic thrombocytopenic purpura in pregnancy: successfultreatment with plasma exchange. Blood Purif 1995; 13: 271-282.
2. Mokrzycki MH, Kaplan AA,. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994; 23: 817-827. (Pubitemid 24173565)
3. Norda R, Berseus O, Stegmayr B,. Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry. Transfus Apher Sci 2001; 25: 33-41. (Pubitemid 33070548)
4. Norda R, Stegmayr BG, Swedish Apheresis G,. Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci 2003; 29: 159-166. (Pubitemid 36993783)
5. Malchesky PS, Koo AP, Roberson GA, Hadsell AT, Rybicki LA,. Apheresis technologies and clinical applications: the 2002 international apheresis registry. Ther Apher Dial 2004; 8: 124-143. (Pubitemid 38796942)
6. Korach JM, Petitpas D, Paris B, Bourgeade F, Passerat V, Berger P, Chillet P, French Registry Group,. Plasma exchange in France: Epidemiology 2001. Transfus Apher Sci 2003; 29: 153-157. (Pubitemid 36993782)
7. Rock G, Clark B, Sutton D, CAG, CAAN,. The Canadian apheresis registry. Transfus Apher Sci 2003; 29: 167-177. (Pubitemid 36993784)
8. Stegmayr B, Ptak J, Wikstrom B,. World apheresis registry report. Transfus Apher Sci 2007; 36: 13-16. (Pubitemid 46341974)
9. Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z,. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial 2005; 9: 391-395. (Pubitemid 43943059)
10. Shemin D, Briggs D, Greenan M,. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher 2007; 22: 270-276. (Pubitemid 350013061)
11. Yeo FE, Bohen EM, Yuan CM, Sawyers ES, Abbott KC,. Therapeutic plasma exchange as a nephrological procedure: a single-center experience. J Clin Apher 2005; 20: 208-216.
12. Kaplan AA,. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008; 52: 1180-1196
13. Silberstein LE, Naryshkin S, Haddad JJ, Strauss JF III,. Calcium homeostasis during therapeutic plasma exchange. Transfusion 1986; 26: 151-155. (Pubitemid 16139665)
14. Weinstein R,. Prevention of citrate reactions during therapeutic plasma exchange by constant infusion of calcium gluconate with the return fluid. J Clin Apher 1996; 11: 204-210. (Pubitemid 27026598)
15. Kankirawatana S, Huang ST, Marques MB,. Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange. J Clin Apher 2007; 22: 265-269. (Pubitemid 350013060)
16. Kamochi M, Aibara K, Nakata K, Murakami M, Nandate K, Sakamoto H, Sata T, Shigematsu A,. Profound ionized hypomagnesemia induced by therapeutic plasma exchange in liver failure patients. Transfusion 2002; 42: 1598-1602.
17. Pearl RG, Rosenthal MH,. Metabolic alkalosis due to plasmapheresis. Am J Med 1985; 79: 391-393. (Pubitemid 15232515)
18. Marques MB, Huang ST,. Patients with thrombotic thrombocytopenic purpura commonly develop metabolic alkalosis during therapeutic plasma exchange. J Clin Apheresis 2001; 16: 120-124. (Pubitemid 32988798)
19. Sonawane S, Kasbekar N, Berns JS,. The safety of heparins in end-stage renal disease. Semin Dial 2006; 19: 305-310. (Pubitemid 44091705)
20. Laird JH, Douglas K, Green R,. HIT type II: a rare but significant complication of plasma exchange. J Clin Apher 2006; 21: 129-131.
21. Reutter JC, Sanders KF, Brecher ME, Jones HG, Bandarenko N,. Incidence of allergic reactions with FFP or Cryo-supernatant plasma in the treatment of TTP. J Clin Apher 2001; 16: 134-138.
22. Stramer SL,. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med 2007; 131: 702-707. (Pubitemid 46729528)
23. Wood L, Jacobs P,. The effect of serial therapeutic plasmapheresis on platelet count, coagulation factors plasma immunoglobulin and complement levels. J Clin Apher 1986; 3: 124-128. (Pubitemid 16129651)
24. Owen HG, Brecher ME,. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion 1994; 34: 891-894. (Pubitemid 24308112)
25. Milliner DS, Shinaberger JH, Shurman P, Coburn JW,. Inadvertent aluminum administration during plasma exchange due to aluminum contamination of albumin replacement solutions. N Engl J Med 1985; 312: 165-167. (Pubitemid 15192865)
26. Vucic S, Davies L,. Safety of plasmapheresis in the treatment of neurologic diseases. Aust N Z J Med 1998; 28: 301-405.
27. Allon M,. Current management of vascular access. Clin J Am Soc Nephrol 2007; 2: 786-800.
28. Bambauer R,. Vascular access in apheresis. Ther Apher Dial 2003; 7: 145-146. (Pubitemid 36753906)
29. Mokrzycki MH, Lok C,. Traditional and non-traditional strategies to optimize catheter function. Kidney Int 2010; 78: 1218-1231.
30. Lok CE, Mokrzycki MH,. Prevention and management of catheter related infection in hemodialysis patients. Kidney Int 2010; 79: 587-598.
31. Sirvent AE, Borras-Blasco J, Enriquez R, Navarro-Ruiz A, Amoros F,. Extracorporeal removal of vancomycin by plasmapheresis. Ann Pharmacother 2006; 40: 2279-2280.
32. Ibrahim RB, Liu C, Cronin SM, Murphy BC, Cha R, Swerdlow P, Edwards DJ,. Drug removal by plasmapheresis: an evidence-based review. Pharmacotherapy 2007; 27: 1529-1549. (Pubitemid 350060208)